Navigation Links
NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium
Date:10/6/2008

TOKYO and CHIPPENHAM, England, October 7 /PRNewswire-FirstCall/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565) and Vectura Group plc ("Vectura"; LSE: VEC), announce results of two Phase II studies evaluating the efficacy, safety and tolerability of NVA237 presented at the annual congress of the European Respiratory Society (ERS) in Berlin, Germany. The new data show that NVA237 (glycopyrronium bromide), a novel inhaled long-acting muscarinic antagonist (LAMA), provides sustained 24-hour bronchodilation in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).

NVA237 showed similar efficacy and duration of action to tiotropium with potentially a more rapid onset of action. In addition, studies lasting up to 28 days showed that NVA237 was safe and well tolerated with no clinically relevant cardiovascular findings.

NVA237 was licensed to Novartis by Sosei and Vectura in 2005 in a deal in which the two companies could receive up to US$ 375 million in milestones as well as royalties on product sales.

COPD affects 210 million people worldwide and is projected to be the third leading cause of death by 2030. It is a progressive lung disease with symptoms including chronic bronchitis and/or emphysema which slowly progress and eventually lead to a largely irreversible loss of lung function. While there is no cure, bronchodilators such as LAMAs make breathing easier by enlarging the patient's airways, and are recognized in international guidelines as first-line treatment for COPD.

One of the randomized, double-blind, placebo-controlled studies compared NVA237 (12.5, 25, 50 and 100microg once-daily) with placebo and open-label tiotropium. In the study involving 83 patients, all doses of NVA237 showed rapid onset of action and sustained 24-hour bronchodilation over the seven-day treatment period.

Clinically relevant improvements (i.e. >120mL more than placebo) in forced expiratory volume in one seco
'/>"/>

SOURCE Sosei Group Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
2. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
3. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
4. Pharmaleads Lead Candidate for Pain, PL37, Enters Phase I
5. Xalieve(TM) Gains Momentum as Calabar AB Launches a Phase II Repeated Dose Study in Dry Mouth Patients
6. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
7. Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology
8. Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3
9. Lilly Announces Initiation of Second Global Phase III Trial of Investigational Alzheimers Disease Compound
10. Bioheart Announces 35 Leading U.S. Heart Failure Centers Engaged in Phase II/III Marvel Trial of Myogenic Cells for Treating Advanced Heart Failure
11. Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)...  The board of directors of AbbVie Inc. (NYSE: ... of $0.42 per share.  The cash ... record at the close of business on Oct. 15, ... research-based biopharmaceutical company formed in 2013 following separation from ... dedicated people and unique approach to innovation to develop ...
(Date:9/19/2014)... WHITEHOUSE STATION, N.J. , Sept. 19, 2014 Merck ... the United States and Canada , ... on Desafiando La Diabetes: Logra Tus Metas , an educational ... of their blood sugar -- a key treatment goal to help ... the United States are at a higher risk for ...
(Date:9/19/2014)... 19, 2014 Larry J. Merlo , President ... will speak before the National Press Club in ... recent move to stop selling tobacco products and its leadership ... health. "Dramatic changes in our health care system ... government," Merlo has said. "CVS Health has a truly unique ...
Breaking Medicine Technology:Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 2Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 3Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 4Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 5CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 3
(Date:9/20/2014)... "As a nurse, patients always ask me how ... from Tamaqua, Pa. "The reason that they cannot tell is ... chairs. My invention enables them to check oxygen levels on ... make it easier to monitor the contents of an oxygen ... tank is low. It allows changeovers to be performed under ...
(Date:9/20/2014)... Los Angeles, CA (PRWEB) September 20, 2014 ... power score of 3.1 out of 5, indicating a ... research firm IBISWorld, this score reflects current and future ... negotiate from historically high prices. Other factors that negatively ... volatility in demand for construction and the moderate switching ...
(Date:9/20/2014)... Wisconsin (PRWEB) September 20, 2014 QueenBeeTickets.com ... the young star’s tour performances. She will visit many ... of February until the 16th of April. , ... Grande Honeymoon Tour tickets at QueenBeeTickets.com. , The star’s ... opportunity to see their favorite young singer in a ...
(Date:9/20/2014)... (PRWEB) September 20, 2014 Final Cut ... announced the release of the Information theme for FCPX filmmakers. ... use to describe the Information theme,” says Christina Austin, CEO ... to look so professional.” , Information features easy to use ... parameters of the environment. Change the background color, color of ...
(Date:9/20/2014)... 2014 The first federal bellwether trial ... its third week in the U.S. District Court, Northern ... documents indicate that the week opened in the ... a DePuy Orthopaedics vice president, who discussed the clinical ... Pinnacle hip replacement. According to Reuters, the executive stated ...
Breaking Medicine News(10 mins):Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 2Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 3Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 4Health News:Discount Ariana Grande Tickets: QueenBeeTickets.com Delights Fans with Discount Concert Tickets for Ariana Grande’s 2015 Honeymoon Tour 2Health News:Today Pixel Film Studios Announced the Release of the Information Theme for Final Cut Pro X 2Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 2Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 3Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 4
... Susan Desmond-Hellmann, MD, MPH, will be inducted today ... alongside some of the world,s other most distinguished ... a renowned oncologist and biotechnology leader who now ... was among five members of the 210 new ...
... technique appears to offer quick and effective relief for ... cancer, researchers reported at the 35th Congress of the ... Many patients with multiple myeloma, or those whose cancer ... fractures in their spine. This is partly because the ...
... Diseases, part of the National Institutes of Health, has ... Virginia Bioinformatics Institute (VBI) and collaborators to determine how ... of the gut. The funding will be used to ... to gut pathogens. "The Center for Modeling Immunity ...
... HealthDay Reporter , FRIDAY, Oct. 8 (HealthDay News) -- Researchers ... may double the odds that a child will develop a ... The study authors aren,t calling for an end to childhood ... such as pneumonia and broken bones. And the study doesn,t ...
... treatment has shown encouraging activity as a first-line therapy ... Congress of the European Society for Medical Oncology (ESMO) ... MD, Mayo Clinic in Florida, presented the results of ... a first-line treatment for metastatic breast cancer. ...
... the European Health Award 2010 handed to the Chronic Disease ... 6 9 October 2010. The ESC was instrumental ... health professionals. The stepping stone was a policy conference organised ... together 10 European health organisations. In just a year, the ...
Cached Medicine News:Health News:UCSF Chancellor inducted into Academy of Arts and Sciences 2Health News:UCSF Chancellor inducted into Academy of Arts and Sciences 3Health News:Surgical technique relieves painful spine fractures in patients with metastatic cancer 2Health News:Virginia Bioinformatics Institute to model immune responses to gut pathogens 2Health News:Virginia Bioinformatics Institute to model immune responses to gut pathogens 3Health News:3 or More X-Rays May Raise Leukemia Risk Among Kids: Study 2Health News:3 or More X-Rays May Raise Leukemia Risk Among Kids: Study 3Health News:Targeted therapy promising for HER2-positive metastatic breast cancer 2Health News:Chronic Disease Alliance receives European Health Award 2010 2Health News:Chronic Disease Alliance receives European Health Award 2010 3Health News:Chronic Disease Alliance receives European Health Award 2010 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: